Treatment of diabetic retinopathy with protein kinase C subtype Β inhibitor

Developments in Ophthalmology

Volumn 39, Issue , 2007, Pages 157-165

  Lang, G ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; INDOLE DERIVATIVE; ISOENZYME; MALEIMIDE DERIVATIVE; PROTEIN KINASE C; PROTEIN KINASE C BETA; RUBOXISTAURIN;

DIABETIC RETINOPATHY; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; METABOLISM; REVIEW; TREATMENT OUTCOME;

DIABETIC RETINOPATHY; ENZYME INHIBITORS; HUMANS; INDOLES; ISOENZYMES; MALEIMIDES; PROTEIN KINASE C; TREATMENT OUTCOME;

EID: 33947517829     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000098506     Document Type: Review

References (25)

1. Donnelly R: Molecular mechanisms, therapeutic targets. Adv Stud Med 2004;3:1008-1013.
2. Dodsen PM: New trends in the management of diabetic retinopathy. Adv Stud Med 2004;3:1002-1012.
3. Hayashi A, Seki N, Hattori A, et al: PKCv, a new member of the protein kinase C family, composes a fourth subfamily with PKCμ. Biochem Biophys Acta 1999;1450:99-106.
4. Idris I, Gray S, Donnelly R: Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologica 2001;44:659-673.
5. Inoue M, Kishimoto A, Takai Y, Nishizuka Y: Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. 2. Proenzyme and its activation by calcium-dependent protease from rat brain. J Biol Chem 1977;252:7610-7616.
6. Kishimoto A, Takai Y, Mori T, et al: Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidylinositol turnover. J Biol Chem 1980;255:2273-2276.
7. Lang GE, Kampmeier J: Die Bedeutung der Proteinkinase C in der Pathophysiologie der diabetischen Retinopathie. Klin Monatsbl Augenheilkd 2002;219:769-776.
8. Lang GE: Pharmacological treatment of diabetic retinopathy. Ophthalmologica, in press.
9. Xia P, Inoguchi T, Kern TS, et al: Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994;43:1122-1129.
10. Craven PA, Davidson CM, DeRubertis FR: Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes 1990;39:667-674.
11. Nishizuka Y: The molecular heterogeneity of protein kinase C and its implication for cellular regulation. Nature 1988;334:661-665.
12. Chakravarthy U, Hayes R, Stitt A, McAuley E, Archer DB: Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 1998;47:945-952.
13. Kreuzer J, Denger S, Schmidts A, et al: Fibrinogen promotes monocyte adhesion via a protein kinase C dependent mechanism. J Mol Med 1996;74:161-165.
14. Malhotra A, Reich D, Nakouzi A, Sanghi V, Greenen DL, Buttrick PM: Experimental diabetes is associated with functional activation of protein kinase C ε and phosphorylation of troponin I in the heart, which are prevented by angiotensin II receptor blockade. Circ Res 1997;81:1027-1033.
15. Li PF, Maasch C, Haller H, et al: Requirement for protein kinase C in reactive oxygen species-induced apoptosis of vascular smooth muscle cells. Circulation 1999;100:967-973.
16. Aiello LP, Bursell SE, Clermont A, et al: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes 1997;46:1473-1480.
17. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robbinson GS, Takagi H, Newsome WP, Jirousek MR, King GL: Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996;98:2018-2026.
18. 1 (IV) transcriptional activity in a reporter mesangial cell line. Am J Physiol 1994;267:632-638.
19. Liao DF, Monia B, Dean N, et al: Protein kinase C-ζ mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells. J Biol Chem 1997;272:6146-6150.
20. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clemont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC-β inhibitor. Science 1996;272:728-731.
21. Danis RP, Bingaman DP, Jirousek M, Yang Y: Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCβ inhibition with LY333531. Invest Ophthalmol Vis Sci 1998;39:171-179.
22. Strom C, Sander B, Klemp K, Aiello LP, Lund-Andersen H, Larsen M: Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest Ophthalmol Vis Sci 2005;46:3855-3858.
23. Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE: Inhibition of PKCβ by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 2006;47:86-92.
24. Campochiaro PA: Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci 2004;45:922-931.
25. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to severe nonproliferative diabetic retinopathy. Diabetes 2005;54:2188-2197.